MX2017001642A - ANTICUERPO IGß ANTIHUMANO NOVEDOSO. - Google Patents

ANTICUERPO IGß ANTIHUMANO NOVEDOSO.

Info

Publication number
MX2017001642A
MX2017001642A MX2017001642A MX2017001642A MX2017001642A MX 2017001642 A MX2017001642 A MX 2017001642A MX 2017001642 A MX2017001642 A MX 2017001642A MX 2017001642 A MX2017001642 A MX 2017001642A MX 2017001642 A MX2017001642 A MX 2017001642A
Authority
MX
Mexico
Prior art keywords
amino acid
cdr
seq
human
acid sequence
Prior art date
Application number
MX2017001642A
Other languages
English (en)
Inventor
Honda Takeshi
Kubo Satoshi
Morinaka Akifumi
Yamajuku Daisuke
SOGA Shinji
SEKI Mutsumi
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of MX2017001642A publication Critical patent/MX2017001642A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/02—Preparation of hybrid cells by fusion of two or more cells, e.g. protoplast fusion
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Problema. Se proporciona un anticuerpo Igß antihumano en el cual BCR y Fc?RIlb se entrecruzan y tiene una función inmunosupresora mejorada en comparación con los anticuerpos convencionales. Solución. Un anticuerpo lgß antihumano que incluye: una región variable de cadena pesada que comprende CDR1 que consiste en la secuencia de aminoácidos de los números de aminoácidos 31 a 35 de la SEC ID NO: 2, CDR2 que consiste en la secuencia de aminoácidos de los números de aminoácidos 50 a 65 de la SEC ID NO: 2 y una CDR3 que consiste en la secuencia de aminoácidos de los números de aminoácidos 98 a 108 de la SEC ID NO: 2, una región variable de cadena ligera que comprende una CDR1 que consiste en la secuencia de aminoácidos de los números de aminoácidos 24 a 38 de la SEC ID NO: 4, una CDR2 que consiste en la secuencia de aminoácidos de los números de aminoácidos 54 a 60 de la SEC ID NO: 4, una CDR3 que consiste en la secuencia de aminoácidos de los números de aminoácidos 93 a 101 de la SEC ID NO: 4 y una región constante de cadena pesada que es una región constante de Ig?1 humana que tiene las mutaciones de aminoácidos de S239D, H268D y L328W.
MX2017001642A 2014-08-06 2015-08-05 ANTICUERPO IGß ANTIHUMANO NOVEDOSO. MX2017001642A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014160141 2014-08-06
PCT/JP2015/072162 WO2016021621A1 (ja) 2014-08-06 2015-08-05 新規抗ヒトＩｇβ抗体

Publications (1)

Publication Number Publication Date
MX2017001642A true MX2017001642A (es) 2017-04-27

Family

ID=55263882

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017001642A MX2017001642A (es) 2014-08-06 2015-08-05 ANTICUERPO IGß ANTIHUMANO NOVEDOSO.

Country Status (22)

Country Link
US (2) US10316086B2 (es)
EP (1) EP3178929B1 (es)
JP (1) JP6627761B2 (es)
KR (1) KR102488214B1 (es)
CN (1) CN106574259B (es)
AR (1) AR102042A1 (es)
AU (1) AU2015300080B2 (es)
BR (1) BR112017002237A2 (es)
CA (1) CA2957313C (es)
ES (1) ES2886443T3 (es)
IL (1) IL250404B (es)
MA (1) MA40321A (es)
MX (1) MX2017001642A (es)
MY (1) MY181914A (es)
PH (1) PH12017500201A1 (es)
PL (1) PL3178929T3 (es)
PT (1) PT3178929T (es)
RU (1) RU2710532C2 (es)
SG (1) SG11201700885SA (es)
TW (1) TWI681971B (es)
UA (1) UA121866C2 (es)
WO (1) WO2016021621A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
GB201412659D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
GB201601075D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies molecules
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
BR112021014420A2 (pt) 2019-01-28 2021-09-21 Tuojie Biotech (Shanghai) Co., Ltd. Anticorpo anti-cd79b, fragmento de ligação ao antígeno do mesmo e uso farmacêutico do mesmo

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101254302B (zh) * 1999-05-07 2011-05-11 杰南技术公司 使用与b细胞表面标志结合的拮抗剂治疗自身免疫病
US20020150573A1 (en) * 2000-11-10 2002-10-17 The Rockefeller University Anti-Igalpha-Igbeta antibody for lymphoma therapy
HUP0402049A3 (en) * 2001-09-25 2009-04-28 Astellas Pharma Inc Recombinant anti-osteopontin antibody and use thereof
US20090068178A1 (en) 2002-05-08 2009-03-12 Genentech, Inc. Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
AU2006252406B2 (en) * 2005-06-01 2012-05-17 California Institute Of Technology Method of targeted gene delivery using viral vectors
EP1941275B1 (en) * 2005-09-29 2013-07-24 Medimmune, Inc. Method of identifying membrane lg specific antibodies and use thereof for targeting immunoglobulin-producing precursor cells
EP2064325B1 (en) * 2006-09-01 2011-12-07 Therapeutic Human Polyclonals, Inc. Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals
AU2008260498B2 (en) * 2007-05-30 2012-11-29 Xencor, Inc. Methods and compositions for inhibiting CD32b expressing cells
PE20140614A1 (es) 2007-07-16 2014-05-28 Genentech Inc Anticuerpos anti-cd79b e inmunoconjugados
SI2247620T1 (sl) 2008-01-31 2016-09-30 Genentech, Inc. Protitelesa proti CD79b in imunokonjugati in postopki za uporabo
JP5964300B2 (ja) * 2010-08-02 2016-08-03 マクロジェニクス，インコーポレーテッド 共有結合型ダイアボディおよびその使用
UA116479C2 (uk) 2013-08-09 2018-03-26 Макродженікс, Інк. БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ

Also Published As

Publication number Publication date
MA40321A (fr) 2021-04-14
CN106574259A (zh) 2017-04-19
PL3178929T3 (pl) 2021-12-20
SG11201700885SA (en) 2017-03-30
US20190309063A1 (en) 2019-10-10
RU2710532C2 (ru) 2019-12-26
EP3178929A1 (en) 2017-06-14
BR112017002237A2 (pt) 2017-11-21
AU2015300080A1 (en) 2017-02-23
AR102042A1 (es) 2017-02-01
ES2886443T3 (es) 2021-12-20
CN106574259B (zh) 2020-11-10
IL250404B (en) 2022-07-01
US20170226207A1 (en) 2017-08-10
CA2957313A1 (en) 2016-02-11
PT3178929T (pt) 2021-09-02
CA2957313C (en) 2023-05-09
JP6627761B2 (ja) 2020-01-08
IL250404A0 (en) 2017-03-30
EP3178929A4 (en) 2018-01-24
MY181914A (en) 2021-01-14
RU2017106743A (ru) 2018-09-06
WO2016021621A1 (ja) 2016-02-11
AU2015300080B2 (en) 2021-04-01
US10316086B2 (en) 2019-06-11
PH12017500201B1 (en) 2017-07-10
RU2017106743A3 (es) 2019-03-22
TWI681971B (zh) 2020-01-11
UA121866C2 (uk) 2020-08-10
PH12017500201A1 (en) 2017-07-10
US11059889B2 (en) 2021-07-13
JPWO2016021621A1 (ja) 2017-06-01
TW201619197A (zh) 2016-06-01
KR102488214B1 (ko) 2023-01-12
KR20170040232A (ko) 2017-04-12
EP3178929B1 (en) 2021-08-04

Similar Documents

Publication Publication Date Title
MX2017001642A (es) ANTICUERPO IGß ANTIHUMANO NOVEDOSO.
MX2019006897A (es) Anticuerpo anti cd73 humana.
CL2019001583A1 (es) Nuevo anticuerpo anti-receptor de transferrina humana capaz de penetrar la barrera hematoencefálica.
MX2017005987A (es) Anticuerpos anti-interleucina(il)-1beta y metodos de uso.
NZ631007A (en) Anti-c5 antibodies having improved pharmacokinetics
PH12016501212B1 (en) Human anti-il-33 neutralizing monoclonal antibody
AU2018256487A1 (en) Antibodies that bind to TL1A and their uses
MX2022011002A (es) Anticuerpos de grupo de diferenciacion 3 (cd3) humanizados o quimericos.
MX2017015042A (es) Anticuerpos cd123 y conjugados de los mismos.
EP4249515A3 (en) Humanized or chimeric cd3 antibodies
NZ628528A (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
NZ630610A (en) Tau peptides, anti-tau antibodies, and methods of use thereof
MX2017005642A (es) Anticuerpos anti-angiopoyetina 2 (ang2) y metodos de uso.
EP4252769A3 (en) Anti-complement factor c1q antibodies and uses thereof
MX2016005765A (es) Anticuerpos anti-il-17, un metodo para producir y utilizar los mismos.
WO2016086175A8 (en) Effector-deficient anti-cd32a antibodies
MX368228B (es) Anticuerpos que se unen específicamente a her2.
PH12021550054A1 (en) Variants of cd38 antibody and uses thereof
WO2017049038A3 (en) Anti-cd115 antibodies
PH12017500699A1 (en) Antibodies that bind to ccr6 and their uses
NZ728981A (en) Anti-ceramide antibodies
MX2019011585A (es) Anticuerpos miltiespecificos estables.
NZ723520A (en) Humanized anti-ige antibodies that crosslink cd23 on b lymphocytes but do not sensitize mast cells
NZ730186A (en) Humanized anti-hepcidin antibodies and uses thereof
MX2016008520A (es) Anticuerpo bdca-2 antihumano novedoso.